Real-time Stock quotes, portfolio, LIVE TV and more.
Jan 01, 2013, 05.32 PM IST
Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.
The company said the product was ready for launch. "Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and company's Maxalt tablets and is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 6 to 17 years old," Aurobindo said in a release.
The annual sale of product is approximately USD 300 million for 12 months ending March 2012, according to IMS. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad.
Aurobindo has a total of 171 ANDA approvals from USFDA.
Tags: Aurobindo Pharma
May 20 2013, 15:05
- in MARKET OUTLOOK
May 20 2013, 12:21
- in Commodities